BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 896 filers reported holding BAXTER INTL INC in Q1 2016. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,037,415 | -29.3% | 120,700 | -9.7% | 0.04% | -25.9% |
Q1 2024 | $5,714,338 | +10.6% | 133,700 | 0.0% | 0.06% | +18.4% |
Q4 2023 | $5,168,842 | +2.4% | 133,700 | 0.0% | 0.05% | -9.3% |
Q3 2023 | $5,045,838 | +9.1% | 133,700 | +31.7% | 0.05% | +20.0% |
Q2 2023 | $4,624,340 | +12.3% | 101,500 | 0.0% | 0.04% | +12.5% |
Q1 2023 | $4,116,840 | -42.8% | 101,500 | -28.1% | 0.04% | -37.5% |
Q4 2022 | $7,195,027 | -45.4% | 141,162 | -42.3% | 0.06% | -36.6% |
Q3 2022 | $13,183,000 | -58.8% | 244,762 | -50.9% | 0.10% | -55.9% |
Q2 2022 | $32,033,000 | +2.3% | 498,729 | +23.5% | 0.23% | +27.9% |
Q1 2022 | $31,314,000 | +45.8% | 403,840 | +61.4% | 0.18% | +35.6% |
Q4 2021 | $21,472,000 | +388.0% | 250,138 | +357.3% | 0.13% | +247.4% |
Q3 2021 | $4,400,000 | +0.7% | 54,700 | +0.7% | 0.04% | +5.6% |
Q2 2021 | $4,371,000 | -21.0% | 54,300 | -17.2% | 0.04% | -26.5% |
Q1 2021 | $5,533,000 | -18.3% | 65,600 | -22.3% | 0.05% | -16.9% |
Q4 2020 | $6,772,000 | +9.4% | 84,400 | +9.6% | 0.06% | -11.9% |
Q3 2020 | $6,192,000 | -64.6% | 77,000 | -62.1% | 0.07% | -67.9% |
Q2 2020 | $17,504,000 | +397.8% | 203,300 | +369.5% | 0.21% | +231.7% |
Q1 2020 | $3,516,000 | -10.9% | 43,300 | -4.0% | 0.06% | +70.3% |
Q3 2019 | $3,945,000 | -61.9% | 45,100 | -64.4% | 0.04% | -60.6% |
Q2 2019 | $10,366,000 | +25.3% | 126,565 | +24.4% | 0.09% | +22.1% |
Q1 2019 | $8,275,000 | +188.6% | 101,765 | +133.6% | 0.08% | +148.4% |
Q4 2018 | $2,867,000 | -14.6% | 43,565 | 0.0% | 0.03% | +6.9% |
Q3 2018 | $3,358,000 | +4.4% | 43,565 | 0.0% | 0.03% | +3.6% |
Q2 2018 | $3,217,000 | +13.6% | 43,565 | 0.0% | 0.03% | +7.7% |
Q1 2018 | $2,833,000 | -64.7% | 43,565 | -64.9% | 0.03% | -62.9% |
Q4 2017 | $8,020,000 | +3.0% | 124,065 | 0.0% | 0.07% | -4.1% |
Q3 2017 | $7,785,000 | +81.2% | 124,065 | +74.8% | 0.07% | +82.5% |
Q2 2017 | $4,296,000 | +90.2% | 70,965 | +62.9% | 0.04% | +110.5% |
Q1 2017 | $2,259,000 | -83.0% | 43,565 | -85.5% | 0.02% | -84.3% |
Q4 2016 | $13,293,000 | +396.0% | 299,798 | +432.5% | 0.12% | +365.4% |
Q3 2016 | $2,680,000 | -7.4% | 56,298 | -12.0% | 0.03% | -21.2% |
Q2 2016 | $2,894,000 | -64.4% | 63,998 | -67.7% | 0.03% | -69.2% |
Q1 2016 | $8,130,000 | +26.4% | 197,900 | +17.4% | 0.11% | +42.7% |
Q4 2015 | $6,432,000 | +97.4% | 168,600 | +239.9% | 0.08% | +74.4% |
Q3 2013 | $3,258,000 | -10.4% | 49,600 | 0.0% | 0.04% | -51.7% |
Q2 2013 | $3,637,000 | – | 49,600 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |